EPRX peer analysis
Eupraxia (EPRX) against its competitors: price, today's move, 1-year return and market value side by side.
EPRX and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| AARD Aardvark Therapeutics | $1.16 | -7.87% | -88.30% | $25.40M |
| IVA Inventiva | $3.28 | -1.20% | -18.00% | $170.50M |
| MDWD MediWound | $13.68 | 0.96% | -25.04% | $176.61M |
| NAUT Nautilus Biotechnology | $2.36 | 12.33% | 31.06% | $300.47M |
| NTHI NeOnc | $4.54 | -7.54% | -50.00% | $130.98M |
| OBIO Orchestra BioMed | $6.99 | -1.83% | 77.41% | $550.15M |
| RNAC Cartesian Therapeutics | $6.08 | -4.25% | -18.50% | $185.46M |
| SLS SELLAS Life Sciences | $17.14 | 129.45% | 1098.60% | $3.49B |
| TARA Protara Therapeutics | $2.32 | -2.52% | -57.89% | $142.84M |
| EPRX Eupraxia | $6.62 | -9.81% | 0.91% | $445.14M |
- EPRX's peers: AARD (Aardvark Therapeutics), IVA (Inventiva), MDWD (MediWound), NAUT (Nautilus Biotechnology), NTHI (NeOnc), OBIO (Orchestra BioMed), RNAC (Cartesian Therapeutics), SLS (SELLAS Life Sciences).
Updated 2026-11-18 05:48 UTC